文献速递糖尿病

1型糖尿病早期与晚期实施强化治疗的获益比较

The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2021-01-01

基于EDIC研究,采用Cox比例风险回归模型估算20年累积发病率与相对风险,分析强化治疗实施时机对肾脏微血管和心血管大血管并发症的影响。结果显示,尽管20年总体血糖暴露相同,前10年HbA1c较低者后续并发症进展风险低于前10年较高者,提示早期强化治疗获益更大。

要点

  • 前10年HbA1c 7%后10年9%者,较相反顺序者CVD风险降低33%、eGFR下降风险降低52%。
  • 20年总体血糖暴露相同时,早期血糖控制更佳者并发症进展风险更低。
  • 1型糖尿病任何时间实施强化治疗均有获益,但更早实施获益更大。

核心结论

  • 在20年模型期内,1型糖尿病早期较晚期实施强化治疗与肾脏和心血管并发症风险更大幅度降低相关。
  • 任何时间实施强化治疗均有获益,但早期实施相对晚期实施获益更大。

研究设计与样本

  • 基于糖尿病干预与并发症流行病学(EDIC)研究,采用Cox比例风险回归模型估算20年累积发病率(绝对风险)和20年相对风险。
  • 分析对象为EDIC随访前20年的心血管疾病(CVD)和估算肾小球滤过率(eGFR)下降,以平均HbA1c为函数。

主要发现

  • 假设患者前10年强化治疗且平均HbA1c 7%(53 mmol/mol)、后10年平均9%(75 mmol/mol),相比前10年平均9%(75 mmol/mol)、后10年强化治疗且HbA1c 7%(53 mmol/mol)者,CVD风险降低33%,eGFR下降风险降低52%。
  • 尽管两患者20年平均血糖暴露相同,前10年HbA1c较低者20年并发症进展风险低于初始HbA1c较高者。

关键数值与推荐

  • CVD风险降低33%,eGFR下降风险降低52%(前10年HbA1c 7%后10年9% vs 前10年9%后10年7%,20年相对风险比较)。

临床怎么用

  • 对1型糖尿病患者应尽早启动强化治疗以降低长期肾脏和心血管并发症风险。
  • 评估长期并发症风险时需关注早期血糖控制轨迹,而非仅看总体平均血糖暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The principal aim is to estimate the benefits of earlier versus later implementation of intensive therapy in type 1 diabetes with respect to the long-term risks of progression of a renal (microvascular) and cardiovascular (macrovascular) complication in the Epidemiology of Diabetes Interventions and Complications (EDIC) study. RESEARCH DESIGN AND METHODS: Cox proportional hazards regression models estimated the 20-year cumulative incidence (absolute risk) and the 20-year relative risk of cardiovascular disease (CVD) and reduced estimated glomerular filtration rate (eGFR) over the first 20 years of EDIC follow-up as a function of the mean HbA1c. RESULTS: A hypothetical patient treated earlier with 10 years of intensive therapy and a mean HbA1c of 7% (53 mmol/mol) followed by 10 years with a mean of 9% (75 mmol/mol) would have a 33% reduction in the risk of CVD and a 52% reduction in reduced eGFR compared with a patient with a mean HbA1c of 9% (75 mmol/mol) over the first 10 years followed by later intensive therapy over 10 years with an HbA1c of 7% (53 mmol/mol). Despite both patients having the same average glycemic exposure over the 20 years, the patient with the lower HbA1c over the first 10 years had a lower risk of progression of complications over the 20 years than the patient who had the higher value initially. CONCLUSIONS: While implementation of intensive therapy at any time in type 1 diabetes will be beneficial, within the 20-year period modeled, earlier relative to later implementation is associated with a greater reduction in the risks of kidney and cardiovascular complications.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lachin JM, Bebu I, Nathan DM, et al. The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care. 2021. PMID: 34380706. doi:10.2337/dc21-1331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。